These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Interval From Initiation of Prasugrel to Coronary Angiography in Patients With Non-ST-Segment Elevation Myocardial Infarction. Silvain J; Rakowski T; Lattuca B; Liu Z; Bolognese L; Goldstein P; Hamm C; Tanguay JF; Ten Berg J; Widimsky P; Miller D; Portal JJ; Collet JP; Vicaut E; Montalescot G; Dudek D; J Am Coll Cardiol; 2019 Mar; 73(8):906-914. PubMed ID: 30819358 [TBL] [Abstract][Full Text] [Related]
27. A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study. Jin C; Kim MH; Bang J; Serebruany V Cardiology; 2017; 138(4):201-206. PubMed ID: 28810251 [TBL] [Abstract][Full Text] [Related]
28. Frequency, Reasons, and Impact of Premature Ticagrelor Discontinuation in Patients Undergoing Coronary Revascularization in Routine Clinical Practice: Results From the Bern Percutaneous Coronary Intervention Registry. Zanchin T; Temperli F; Karagiannis A; Zanchin C; Räsänen M; Koskinas KC; Stortecky S; Hunziker L; Praz F; Blöchlinger S; Moro C; Moschovitis A; Seiler C; Billinger M; Heg D; Pilgrim T; Valgimigli M; Windecker S; Räber L Circ Cardiovasc Interv; 2018 May; 11(5):e006132. PubMed ID: 29748219 [TBL] [Abstract][Full Text] [Related]
29. One-year post-discharge resource utilization and treatment patterns of patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with ticagrelor or prasugrel. Simeone JC; Molife C; Marrett E; Frech-Tamas F; Effron MB; Nordstrom BL; Zhu YE; Keller S; Murphy BR; Nair KV; Vetrovec GW; Page RL; McCollam PL Am J Cardiovasc Drugs; 2015 Oct; 15(5):337-50. PubMed ID: 26359016 [TBL] [Abstract][Full Text] [Related]
30. Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: the ACCOAST-PCI study. Montalescot G; Collet JP; Ecollan P; Bolognese L; Ten Berg J; Dudek D; Hamm C; Widimsky P; Tanguay JF; Goldstein P; Brown E; Miller DL; LeNarz L; Vicaut E; J Am Coll Cardiol; 2014 Dec; 64(24):2563-2571. PubMed ID: 25524333 [TBL] [Abstract][Full Text] [Related]
31. Outcomes Among Clopidogrel, Prasugrel, and Ticagrelor in ST-Elevation Myocardial Infarction Patients Who Underwent Primary Percutaneous Coronary Intervention From the TOTAL Trial. Welsh RC; Sidhu RS; Cairns JA; Lavi S; Kedev S; Moreno R; Cantor WJ; Stankovic G; Meeks B; Yuan F; Džavík V; Jolly SS Can J Cardiol; 2019 Oct; 35(10):1377-1385. PubMed ID: 31492492 [TBL] [Abstract][Full Text] [Related]
32. Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database. Blin P; Dureau-Pournin C; Benichou J; Bonello L; Dallongeville J; Danchin N; Falissard B; Thomas-Delecourt F; Jové J; Lassalle R; Droz C; Moore N Atherosclerosis; 2019 Feb; 281():98-106. PubMed ID: 30658197 [TBL] [Abstract][Full Text] [Related]
33. Pre-treatment with P2Y12 inhibitors in ACS patients: who, when, why, and which agent? Sibbing D; Kastrati A; Berger PB Eur Heart J; 2016 Apr; 37(16):1284-95. PubMed ID: 26712838 [TBL] [Abstract][Full Text] [Related]
34. Average daily ischemic versus bleeding risk in patients with ACS undergoing PCI: Insights from the BleeMACS and RENAMI registries. D'Ascenzo F; Biolè C; Raposeiras-Roubin S; Gaido F; Abu-Assi E; Kinnaird T; Ariza-Solé A; Liebetrau C; Manzano-Fernández S; Boccuzzi G; Henriques JPS; Templin C; Wilton SB; Omedè P; Velicki L; Xanthopoulou I; Correia L; Cerrato E; Rognoni A; Fabrizio U; Nuñez-Gil I; Montabone A; Taha S; Fujii T; Durante A; Song X; Gili S; Magnani G; Autelli M; Bongiovanni F; Grosso A; Kawaji T; Blanco PF; Garay A; Quadri G; Alexopoulos D; Queija BC; Huczek Z; Paz RC; González-Juanatey JR; Fernández MC; Nie SP; Pousa IM; Kawashiri MA; Rettegno S; Gallo D; Morbiducci U; Conrotto F; Dominguez-Rodriguez A; Valdés M; Cequier A; Iñiguez-Romo A; Biondi-Zoccai G; Stone GW; De Ferrari GM Am Heart J; 2020 Feb; 220():108-115. PubMed ID: 31809991 [TBL] [Abstract][Full Text] [Related]
35. Design and Rationale of the APELOT Trial: A Randomized, Open-Label, Multicenter, Phase IV Study to Evaluate the Antiplatelet Effect of Different Loading Dose of Ticagrelor in Patients With Non-ST Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Liu HL; Wei YJ; Jin ZG; Zhang J; Ding P; Yang SL; Luo JP; Ma DX; Liu Y; Han W Medicine (Baltimore); 2016 May; 95(22):e3756. PubMed ID: 27258504 [TBL] [Abstract][Full Text] [Related]
36. One-Year Clinical Effectiveness Comparison of Prasugrel with Ticagrelor: Results from a Retrospective Observational Study using an Integrated Claims Database. Effron MB; Nair KV; Molife C; Keller SY; Page RL; Simeone JC; Murphy B; Nordstrom BL; Zhu Y; McCollam PL; Vetrovec GW Am J Cardiovasc Drugs; 2018 Apr; 18(2):129-141. PubMed ID: 29222628 [TBL] [Abstract][Full Text] [Related]
37. Usefulness of the PARIS Score to Evaluate the Ischemic-hemorrhagic Net Benefit With Ticagrelor and Prasugrel After an Acute Coronary Syndrome. Raposeiras-Roubín S; Caneiro Queija B; D'Ascenzo F; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Quadri G; Rognoni A; Boccuzzi G; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Flores Blanco P; Garay A; Varbella F; Tomassini F; Cobas Paz R; Cespón Fernández M; Muñoz Pousa I; Gallo D; Morbiducci U; Domínguez-Rodríguez A; Baz-Alonso JA; Calvo-Iglesias F; Valdés M; Cequier Á; Gaita F; Alexopoulos D; Íñiguez-Romo A; Abu-Assi E Rev Esp Cardiol (Engl Ed); 2019 Mar; 72(3):215-223. PubMed ID: 30029980 [TBL] [Abstract][Full Text] [Related]
38. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis. Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684 [TBL] [Abstract][Full Text] [Related]
39. MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry. Clemmensen P; Grieco N; Ince H; Danchin N; Goedicke J; Ramos Y; Schmitt J; Goldstein P; Eur Heart J Acute Cardiovasc Care; 2015 Jun; 4(3):220-9. PubMed ID: 25182465 [TBL] [Abstract][Full Text] [Related]
40. Comparison of healthcare resource utilization and costs in patients hospitalized for acute coronary syndrome managed with percutaneous coronary intervention and receiving prasugrel or ticagrelor. Molife C; Frech-Tamas F; DeKoven M; Effron MB; Karkare S; Zhu Y; Larmore C; Lu J; McCollam P; Marrett E; Vetrovec GW J Med Econ; 2015; 18(11):898-908. PubMed ID: 26086414 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]